EOLS - エボラス (Evolus Inc.) エボラス

 EOLSのチャート


 EOLSの企業情報

symbol EOLS
会社名 Evolus Inc (エボラス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エヴォルス(Evolus Inc.)は医療美容会社である。同社は医師および美容処置・治療法を提供することに重点を置く。また、自費の美容市場を提供することに焦点を当てる。製品候補であるPrabotulinumtoxinA(DWP-450)は大規模かつ成長的美容市場のニーズに対応する注入可能な900キロダルトンのボツリヌス毒素タイプである。同社は医師と患者にDWP-450による提案を提供する。OnabotulinumtoxinA(BOTOX)は米国にある神経毒素認可900kDaボツリヌス毒素A型複合体である。   エボラスは米国の医療審美企業。医師および患者に審美・美容手術や治療法での広範な選択肢を提供する。また、自己負担における医療市場に注力する。主な候補薬には、市場でニ―ズの高い900キロダルトン分子形態のA型ボツリヌス毒素注射剤「DWP-450」などがある。本社所在地はカリフォルニア州ア―バイン。   Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.
本社所在地 17901 Von Karman Avenue Suite 150 Irvine CA 92614 USA
代表者氏名 Vikram Malik ヴィクラム・マリク
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 949-284-4555
設立年月日 41214
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.evolus.com
nasdaq_url https://www.nasdaq.com/symbol/eols
adr_tso
EBITDA EBITDA(百万ドル) -18.51500
終値(lastsale) 16.43
時価総額(marketcap) 438270102.13
時価総額 時価総額(百万ドル) 438.27010
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 411.15510
当期純利益 当期純利益(百万ドル) -17.56000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Evolus Inc revenues was not reported. Net loss increased from $6.3M to $22.6M. Higher net loss reflects Revaluation of contingent royalty obliga increase from $0K to $9.1M (expense) General and Administrative - Balancing v increase from $1.8M to $6.8M (expense) Stock-based Compensation in SGA increase from $232K to $2.9M (expense).

 EOLSのテクニカル分析


 EOLSのニュース

   Global Online Flowchart Software Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027  2021/05/20 18:30:00 Ken Research
The global Online Flowchart Software market is expected to reach USD XX Million by 2027, with a CAGR of XX% from 2020 to 2027, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America). By Market Verdors: Visio Nulab Jgraph MyDraw EDrawSoft Gliffy Cinergix Omni Group Slickplan The Dia Developers Computer Systems Odessa iGrafx Evolus yworks By Types: Cloud-based On-premises By Applications: Small and Medium Enterprises (SMEs) Large Enterprises Key Indicators Analysed Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market''s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
   Evolus Appoints Dan Stewart as Vice President and General Manager, International  2021/05/19 00:00:00 BioSpace
Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the appointment of Dan Stewart as Vice President and General Manager of the companys International business.
   Evolus: Q1 Earnings Have Forced A Bottom  2021/05/17 05:32:51 Seeking Alpha
   Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics?  2021/05/13 13:31:00 PR Newswire
NEW YORK, May 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HRTX, CSPR, EOLS, XERS, and ATRA. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.
   Evolus, Inc. (EOLS) CEO David Moatazedi on Q1 2021 Results - Earnings Call Transcript  2021/05/13 02:44:03 Seeking Alpha
   Repeat Doses Of Evolus' Frown Lines Treatment Are Safe, With Decreasing Rates Of Adverse Events  2021/05/12 14:33:21 Benzinga
Evolus Inc (NASDAQ: EOLS ) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumtoxinA (Jeuveau) to decrease the appearance of glabellar lines (also known as frown lines between the eyes). The … Full story available on Benzinga.com
   AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus  2021/02/19 15:29:09 Endpoints News
The crown jewel of AbbVie's big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma — and both drugmakers have worked overtime to protect its advantage. After scoring a fatal blow to Evolus' chances as a major competitor late last year, AbbVie is now putting the
   80 Biggest Movers From Yesterday  2020/12/18 09:47:14 Benzinga
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS ) shares climbed 473.7% to close at $33.96 on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma shares gained around 8% on Wednesday after the company priced its IPO at $5.5 per share. MingZhu Logistics Holdings Ltd (NASDAQ: YGMZ ) shares surged 336.4% to close at $17.50. Wunong Net Technology Company Limited (NASDAQ: WNW ) shares climbed 88.2% to close at $122.50 after jumping 440% on Wednesday. The company, on Tuesday, priced its IPO at $5 per share. Nxt-ID, Inc. (NASDAQ: NXTD ) gained 54.2% to close at $1.4250 after jumping around 90% on Wednesday. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 47.7% to close at $5.45 after the company issued regulatory update for IV Tramadol. Boqii Holding Limited (NYSE: BQ ) rose 46.1% to close at $7.00. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) gained 34.4% to close at $9.11. Vivos Therapeutics, earlier during the month, priced its IPO at $6 a share.
   EOLS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Evolus, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: December 15, 2020  2020/12/14 16:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. ("Evolus” or "the Company") (NASDAQ: EOLS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Evolus securities between February 1, 2019 to July 6, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/eols. This class acti
   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Evolus, Inc. (EOLS)  2020/12/11 16:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $EOLS #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) securities between February 1, 2019 and July 6, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On July 6, 2020, the U.S. International Trade Commission (“ITC”)
   Repeat Doses Of Evolus' Frown Lines Treatment Are Safe, With Decreasing Rates Of Adverse Events  2021/05/12 14:33:21 Benzinga
Evolus Inc (NASDAQ: EOLS ) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumtoxinA (Jeuveau) to decrease the appearance of glabellar lines (also known as frown lines between the eyes). The … Full story available on Benzinga.com
   AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus  2021/02/19 15:29:09 Endpoints News
The crown jewel of AbbVie's big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma — and both drugmakers have worked overtime to protect its advantage. After scoring a fatal blow to Evolus' chances as a major competitor late last year, AbbVie is now putting the
   80 Biggest Movers From Yesterday  2020/12/18 09:47:14 Benzinga
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS ) shares climbed 473.7% to close at $33.96 on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma shares gained around 8% on Wednesday after the company priced its IPO at $5.5 per share. MingZhu Logistics Holdings Ltd (NASDAQ: YGMZ ) shares surged 336.4% to close at $17.50. Wunong Net Technology Company Limited (NASDAQ: WNW ) shares climbed 88.2% to close at $122.50 after jumping 440% on Wednesday. The company, on Tuesday, priced its IPO at $5 per share. Nxt-ID, Inc. (NASDAQ: NXTD ) gained 54.2% to close at $1.4250 after jumping around 90% on Wednesday. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 47.7% to close at $5.45 after the company issued regulatory update for IV Tramadol. Boqii Holding Limited (NYSE: BQ ) rose 46.1% to close at $7.00. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) gained 34.4% to close at $9.11. Vivos Therapeutics, earlier during the month, priced its IPO at $6 a share.
   EOLS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Evolus, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: December 15, 2020  2020/12/14 16:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. ("Evolus” or "the Company") (NASDAQ: EOLS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Evolus securities between February 1, 2019 to July 6, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/eols. This class acti
   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Evolus, Inc. (EOLS)  2020/12/11 16:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $EOLS #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) securities between February 1, 2019 and July 6, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On July 6, 2020, the U.S. International Trade Commission (“ITC”)

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エボラス EOLS Evolus Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)